LARIMAR THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
LARIMAR THERAPEUTICS, INC. (LRMR) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $5.88 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.88M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.88M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.49M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.71M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $5.88M 10-K · filed 2026-03-19 |
| 2024-12-31 | $4.88M 10-K · filed 2026-03-19 |
| 2023-12-31 | $3.49M 10-K · filed 2025-03-24 |
| 2022-12-31 | $2.71M 10-K · filed 2024-03-14 |
| 2021-12-31 | $1.46M 10-K · filed 2023-03-14 |
| 2020-12-31 | $490.00K 10-K · filed 2022-03-25 |
| 2019-12-31 | $3.24M 10-K · filed 2020-03-05 |
| 2018-12-31 | $4.37M 10-K · filed 2020-03-05 |
| 2017-12-31 | $5.57M 10-K · filed 2019-03-14 |
| 2016-12-31 | $6.03M 10-K · filed 2018-03-09 |
| 2015-12-31 | $2.78M 10-K · filed 2017-03-10 |
| 2014-12-31 | $428.00K 10-K · filed 2016-03-15 |
| 2013-12-31 | $91.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |